Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: a conservative approach

Authors

  • Kalpana Singh Department of Reproductive Biology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
  • Geetam Bharati Department of Reproductive Biology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
  • Dipali Prasad Department of Reproductive Biology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
  • Smita Kumari Department of Reproductive Biology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20170396

Keywords:

Adenomyosis, Endometrial hyperplasia, Endometriosis, Fibroid, Heavy menstrual bleeding, LNG IUS

Abstract

Background: Heavy menstrual bleeding (HMB) is defined as prolonged (>7 days) or excessive menstrual blood loss greater than or equal to 80 ml per menstrual cycle. The objective of the study was to assess the efficacy, acceptability and side effects of LUS IUS in women with heavy menstrual bleeding.

Methods: 42 women with heavy menstrual bleeding with or without associated dysmenorrhoea or chronic pelvic pain and had no contraindication to IUS insertion were included in the study. Patients having active genital tract infection, suspicion of pregnancy, uterine fibroids >2.5 cm in size or sub mucosal distorting the uterine cavity, uterine size >12 weeks, atypical endometrial hyperplasia or malignancy, abnormal cervical cytology, coagulopathy or liver disease were excluded from the study. Preliminary endometrial biopsy was done to rule out malignancy and LNG IUS was inserted under anaesthesia. Women were followed for 3,6,12 and 24 months post insertion.

Results: In first 3 months, 20% patients achieved normal menstrual cycle, and at 6 months 44.44% had scanty menstrual flow and after 1 year of use 81.5% achieved amenorrhoea. In initial 3 months 37.5% patients had irregular heavy bleeding, which reduced to 13.89% at 6 months and 0% at 1 year follow up. Irregular spotting was second most complaint in 32.5% patients in initial 3 months that persisted in 7.4% patients at 1year follow up. In 5.0% patients, there was spontaneous expulsion of the device in first 3 menstrual cycles. After 3 months of use 57.5% patients were satisfied with the device and at the end of 1 year 92.5% were satisfied.

Conclusions: LNG IUS is highly effective in controlling blood loss, well tolerated and better alternative for hysterectomy with higher user satisfaction in all age group of women.

References

Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow up data. Am J Obstet Gynecol. 2004;190(5):1216-23.

Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;(4):CD002126.

Mansour D. Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol. 2007;21(6):1007-21.

Sheng J1, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189-93.

Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (LNG): a 3-year follow-up. Hum Reprod. 2005;20(3):789-93.

Gorgen H, Api M, Akça A, Cetin A. Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009;279:835-40.

Lete I, Obispo C, Izaguirre F, Orte T, Rivero B, Cornellana MJ, et al. The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care 2008;13(3):231-7.

El-Hemaidi I, Gharaibeh A, Shehata H. Menorrhagia and bleeding disorders. Curr Opin Obstet Gynecol. 2007;19(6):513-20.

McPherson K, Metcalfe MA, Herbert A, Maresh M, Casbard A, Hargreaves J, et al. Severe complications of hysterectomy: the VALUE study. BJOG. 2004;111(7):688-94.

Chrisman C, Ribeiro P, Dalton VK. The levonorgestrel-releasing intrauterine system: an updated review of the contraceptive and non-contraceptive uses. Clin Obstet Gynecol. 2007;50(4):886-97.

American college of Obstetricians and Gynecologists: Noncontraceptive uses of the levonorgestrel intrauterine system. ACOG Committee Opinion No. 337. Obstet Gynecol. 2006;107:1479-82.

Garg S, Soni A. A Non- surgical lifeline for Abnormal uterine bleeding (AUB) - the LNG IUS. Ind J Obstet Gynecol Res. 2016;3(1):23-27.

Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97(3):190-4.

Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to 2 years. Contraception. 2002;65(2):129-32.

Baldaszti E, Puchinger WB, L¨oschke K. Acceptability of long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception. 2003;67(2):87-91.

Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen(levonorgestrel): a 3- year follow-up. Hum Reprod. 2005;20(3):789-93.

Tariq N, Ayub R, Jaffery T, Rahim F, Naseem F, Kamal M. Efficacy of Levonorgestrel Intrauterine System (LNG-IUS) for Abnormal Uterine Bleeding and Contraception. J Coll Physicians Surg Pak. 2011;21(4):210-3.

Yazbeck C, Omnes S, Lavenu VMC, Madelenat P. Levonorgestrel-releasing intrauterine system in the treatment of dysfunctional uterine bleeding: A French multicenter study. Gynecol Obstet Fertil. 2006;34:906-13.

Downloads

Published

2017-01-31

Issue

Section

Original Research Articles